

RESEARCH UPDATE

Dave Storms, CFA
dave@stonegateinc.com

214-987-4121

Market Statistics in USD

Price	\$ 1.73
52 week Range	\$1.50 - \$12.68
Daily Vol (3-mo. average)	28,450
Market Cap (M)	\$ 31.4
Enterprise Value (M)	\$ 28.2
Shares Outstanding: (M)	17.6
Float (M)	13.4
Public Ownership	72.1%
Institutional Ownership	3.9%

Financial Summary in USD


Cash (M)	\$ 3.6
Cash/Share	\$ 0.21
Debt (M)	\$ 0.4
Equity (M)	\$ 6.6
Equity/Share	\$ 0.37

FYE: Jun	2024	2025E	2026E
EBITDA	\$ (18.4)	\$ (28.9)	\$ (32.9)
Net Income	\$ (18.5)	\$ (28.9)	\$ (32.9)
EPS	\$ (1.15)	\$ (1.61)	\$ (1.83)
EV/R&D	2.9x	1.2x	0.9x
EV/EBITDA	-2.0x	-1.0x	-0.9x
P/E	-2.6x	-1.1x	-0.9x

(all figures in M, except per share information)

EBITDA	\$ (18.4)	\$ (28.9)	\$ (32.9)
Net Income	\$ (18.5)	\$ (28.9)	\$ (32.9)
EPS	\$ (1.15)	\$ (1.61)	\$ (1.83)

EV/R&D	2.9x	1.2x	0.9x
EV/EBITDA	-2.0x	-1.0x	-0.9x
P/E	-2.6x	-1.1x	-0.9x


Company Description

Incannex Healthcare, Inc. is a clinical-stage biopharmaceutical development company focused on developing innovative medicines for patients living with chronic diseases and significant unmet need. Incannex is advancing proprietary, synthetic first- and best-in-class cannabinoid and psychedelic-assisted therapeutics targeting sleep apnea, anxiety, and inflammatory diseases. Incannex's lead programs include IHL-42X for the treatment of obstructive sleep apnea (OSA), Psi-GAD in development to assess the use of psilocybin-assisted therapy for generalized anxiety disorder (GAD), and IHL-675A in Phase 2 trials for rheumatoid arthritis (RA). Each of these programs target conditions for which there are either no approved treatments or the available treatments are inadequate.

INCANNEX HEALTHCARE INC. (NASDAQGM: IXHL)
Company Summary

Quarterly Update: During 1Q25 the Company reported research and development costs of \$2.9M, an increase of \$0.3M from 1Q24. We expect R&D costs to continue to climb as the Company focuses on getting its drug candidates across the finish line. IXHL recovered 28.0% of these costs with an R&D tax incentive of \$0.8M. We expect that this will normalize around 43.5% for the foreseeable future. The Company results for the quarter were an EPS loss of \$0.29 per share.

Leadership Updates: In October of 2024 the Company appointed Lou Barbato, M.D. as Chief Medical Officer. Dr. Barbato has over 25 years of experience in the industry with expertise in psychiatric and neurological disorders. Dr. Barbato's work spans a variety of drug classes including synthetic cannabinoids, SSRIs, and MAO inhibitors.

Equity Line of Credit: Recently Incannex completed a strategic financing agreement with Arena Investors. This transaction strengthens Incannex's ability to advance their lead programs through key late-stage clinical milestones by providing up to \$59.0M in liquidity to Incannex. This is divided between a \$50.0M equity line of credit and the sale in future closings of convertible debentures with an aggregate principal amount of up to \$9.0M. We view this as further proof that the Company still has access to financing.

IHL-42X Update: IHL-42X is a novel treatment designed to treat people suffering from Obstructive Sleep Apnea (OSA) which is characterized by interrupted breathing while asleep. Most recently the Company has initiated dosing for the Phase 2/3 FDA trial. This trial will encompass 560 patients in a randomized double-blind safety and efficacy study. Top line results are expected in the first half of calendar 2025. Additionally, the Company is expecting results from its 115 participant TGA bioavailability and bioequivalence clinical trial to be available before the end of Calendar 2024.

PSX-001 Update: PSX-001 is Incannex's psilocybin drug product designed for use with psychological therapy to treat people suffering from Generalized Anxiety Disorder (GAD). Most recently the Company has announced positive top line results from the Phase 2 TGA proof of concept trial. The psilocybin and psychotherapy combination was observed to significantly reduce anxiety scores in patients. Additionally, IXHL has received IND clearance from the FDA and Clinical Trial Authorization from the UK Medicines and Healthcare Products Regulatory Agency, further derisking the asset.

IHL-675A Update: IHL-675A is a novel treatment designed to treat people suffering from inflammation which is a major contributing factor to rheumatoid arthritis. Most recently the Company completed dosing a TGA phase 2 clinical trial. This trial is planned to include approximately 128 subjects, with top line date expected in the second half of 2025.

Valuation: We use a probability-adjusted Discounted Cash Flow Model when valuing IXHL. Our valuation model returns a valuation range of \$5.07 to \$5.93 with a midpoint of \$5.49 based on a discount rate range of 12.25% to 12.75% and a current risk adjustment range of 14% to 16%. Further details on our model can be found on page 5 of this report. We note that this model is highly levered to the out years due to the long term nature of IXHL's industry, leading to the potential for dramatic re-ratings as new information becomes available.

refundable tax offsets for R&D activities equal to approximately 43.5% of R&D activities in the year. Financing of company operations has historically been through equity issuance. To date the Company has not had issues raising funds for operations and we do not have any current concerns that the Company will be unable to finance future operations.

Assets

IHL-42X

IHL-42X is a novel treatment designed to treat people suffering from Obstructive Sleep Apnea (OSA) which is characterized by interrupted breathing while asleep. OSA is a highly prevalent condition where current treatments have poor patient compliance and no approved pharmacotherapies. What makes IHL-42X interesting is its unique combination of dronabinol and acetazolamide, addressing two different physiological aspects of OSA. Dronabinol binds to cannabinoid receptors, modulates signaling, and activates muscles that dilate the airway whereas acetazolamide induces metabolic acidosis which signals to the body that there is excess CO₂ in the blood, inducing the taking of a breath. Both of these compounds have been approved in the US for other treatments, leading to the potential reduced timeline to market.

Exhibit 3: IHL-42X Clinical Development Status

Obstructive Sleep Apnea			
IHL-42X	RePOSA	Ph 2/3 Safety and Efficacy Trial	• 560 patient, randomized, double-blind safety and efficacy study • Dosing started May 2024
	BABE	Bioavailability Trial	• 115 subject, bioavailability and bioequivalence study • Dosing completed July 2024
	POC	Proof of Concept Ph 2 Trial	• Proof of concept, cross over, safety and efficacy study • Study completed

Source: Company Reports

Currently IHL-42X is in an FDA phase 2/3 clinical trials with the opportunity to achieve breakthrough designation and or registration. Phase 3 will be conducted across 55 sites and 440 patients. We expect the Company to meet with the FDA to establish next steps to meet regulatory requirements followed by discussion with other regulatory agencies to acquire approval in other jurisdictions. Should IHL-42X be approved, the Company has a large addressable market opportunity including a current \$8.2B market for sleep apnea devices. It is notable that this market is plagued by patients who tend to be non-compliant with current treatments like positive airway pressure (PAP) machines. This leaves space for pharmaceutical treatments that are both effective and less intrusive than current offerings in the market.

Exhibit 4: IHL-42X Market Overview




Source: Company Reports

The Company expects to report top-line data from the Phase 2 portion this pivotal U.S. Phase 2/3 clinical trial in the first half of 2025 and to release top-line results from our pharmacokinetic and safety study in 2024.

PSX-001

PSX-001 is Incannex's psilocybin drug is designed for use with psychological therapy to treat people suffering from Generalized Anxiety Disorder (GAD) which is characterized by its diffuse, excessive, uncontrollable worry that is not restricted to any specific environmental circumstances. Treatment of GAD remains inadequate, with less than half of patients achieving remissions with currently accepted treatments. What makes Psi-GAD interesting is its use of psilocybin to facilitate access to fundamental causes of anxiety, and providing a remarkable opportunity for patients to make real and lasting changes via psychotherapy.

Exhibit 3: Psi-GAD2 Treatment Timeline

Source: Company Reports

Generalized Anxiety Disorder is a highly prevalent disorder, with an estimated 7 million people in the US and 1 million people in Australia having moderate to severe GAD. To study the effectiveness of PSX-001 the primary endpoint is a change in the patients' anxiety score (HAM-A) 2 weeks following the second dosing session, as compared to the baseline. Currently the Company is planning a trial across 94 patients across 8 sites in the UK and US across 2 patient arms. Results from a completed Therapeutics Goods Administration (TGA) Phase 2 trial conducted in Australia (PsiGAD1) are meaningful with clinical response scores that are four times higher than the placebo group.

The Company anticipates reporting full data results from PsiGAD1 in the first half of FY2025.

Exhibit 4: Psi-GAD Clinical Development Status

Generalized Anxiety Disorder			
PSX-001	PsiGAD2	Ph 2 Dose Comparison	• 94 patient, double-blind, safety and efficacy study • Dosing expected to begin H1 2025
	PsiGAD1	Proof of Concept Ph 2 Trial	• 73 patient, double-blind, safety and efficacy study • Dosing completed Jan 2024

Source: Company Reports

IHL-675A

IHL-675A is a novel treatment designed to treat people suffering from inflammation, which is a major contributing factor to rheumatoid arthritis, with many patients not responding to current drug treatments. IHL-675A targets two components of the inflammatory pathway by combining two anti-inflammatory drugs, CBD and hydroxychloroquine sulfate (HCQ). Incannex has demonstrated that IHL-675A reduced disease severity in an animal model of rheumatoid arthritis to a greater extent than either CBD or hydroxychloroquine sulfate alone. HCQ and CBD seem to work synergistically to inhibit production of inflammatory cytokines.

The addressable market for this rheumatoid arthritis treatment is estimated at \$60.1B. The Company is currently running a phase 2 trial (128 patients across 10 sites) in Australia and anticipates reporting top-line data in the second half of 2025.

Exhibit 5: IHL-675A Clinical Development Status**Rheumatoid Arthritis**

IHL-675A	Phase 2	Ph 2 Safety and Efficacy Study	• 128 patient, double-blind, safety and efficacy study • Dosing started Jan 2024
	Phase 1	Ph 1 Safety and PK Study	• 36 patient, Phase 1 safety and PK study • Study completed

Source: Company Reports

Additional Assets

Additional assets include cannabinoid chewables designed to treat addiction. Incannex holds multiple patents for chewable cannabinoid-based drug candidates that also contain nicotine or opioid agonists and/or antagonists. Opioid use disorder has an estimated addressable market of \$4.59B, and the nicotine chewing gum market was \$5.2B in 2020.

The Company is also working to use a combination of CBD and CBG to treat dermatological conditions caused by disorders of the immune system that include vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema. There is no topical cannabinoid products that have achieved regulatory approval for any skin condition, giving the Company access to the \$1.2B Vitiligo market, the \$26.4B psoriasis market, and the \$11.8B atopic dermatitis market. Patents are pending for compositions and methods of us for treatment of these skin conditions with the next steps being Phase 2 clinical trials in Australia.

Risks

As with any investment, there are certain risks associated with Incannex's operations as well as with the surrounding economic and regulatory environments common to the pharmaceutical industry.

- The Company has no history of net income, dividends, or cash flow and there can be no assurance that the Company will be profitable going forward. In the case that the Company cannot create enough revenue to sustain on-going business activities, the Company's most likely source of financing will be through the sale of existing securities or high-cost borrowing.
- Currently the Company has enough funds to sustain it through the foreseeable future and does not pose a going concern risk. We do however recognize that the Company will most likely need to raise more funds to sustain its operations until it begins revenue generation. Should the Company be unable to raise the necessary funds this would create a going concern risk.
- The Company is subject to regulatory risk as pharmaceutical activities are subject to laws and regulations imposed by local and state government authorities. Any future changes in the laws, regulations, agreements, or judicial rulings could impact the Company's potential portability.
- Should the Company bring any or all of its assets to market, there is no guarantee that a profitable market will exist for those treatments.

VALUATION SUMMARY

We use a probability-adjusted Discounted Cash Flow Model when valuing IXHL. Our valuation model returns a valuation range of \$5.07 to \$5.93 with a midpoint of \$5.49 based on a discount rate range of 12.25% to 12.75% and a current risk adjustment range of 14% to 16%. Key assumptions in this valuation include the tax incentive rate remaining at 43.5%, a current total market size of approximately 89.3B, a total market size CAGR of 4% over the foreseeable future, and a steadily increasing market capture percentage. Uncertainties that would have a significant impact on this model would be variances in the time to market for any of the three leading drug candidates which would impact the risk rating, the capital needs of IXHL going forward which would impact the shares outstanding, and any changes to market capture due to a number of variables that would influence the Company's revenue potential. We note that this model is highly levered to the out years due to the long term nature of IXHL's industry, leading to the potential for dramatic re-ratings as new information becomes available. Currently we believe the Company will begin revenue generation as early as FY27, with operating profitability beginning in FY31.

BALANCE SHEET

Incannex Healthcare Inc.
Consolidated Balance Sheets (\$M)
Fiscal Year End: June

ASSETS	FY 2022	FY 2023	FY 2024	Q1 Sep-24
Cash and Cash Equivalents	37.5	22.1	5.9	3.6
Prepaid Expenses and Other Assets	0.4	0.9	0.5	0.5
R&D Tax Incentive Receivable	-	-	9.8	11.1
Total Current Assets	37.9	23.0	16.2	15.2
Property, Plant, and Equipment, net	-	0.3	0.5	0.4
Operating Lease ROU Assets	-	0.5	0.4	0.4
Total Assets	37.9	23.8	17.0	16.0
LIABILITIES AND SHAREHOLDERS' EQUITY				
Trade and Other Payable	2.0	1.7	0.6	1.6
Accrued Expenses	-	0.7	4.8	7.5
Operating Lease Liabilities, Current	-	0.1	0.2	0.2
Total Current Liabilities	2.0	2.6	5.6	9.2
Operating Lease Liabilities, Non-Current	-	0.4	0.2	0.2
Total Liabilities	2.0	3.0	5.8	9.5
Common Stock	-	0.0	0.0	0.0
Preferred Stock	-	-	-	-
Additional Paid-In Capital	94.7	116.3	125.2	125.7
Accumulated Deficit	(58.8)	(92.2)	(110.7)	(116.1)
Foreign Currency Translation Reserve	-	(3.3)	(3.3)	(3.0)
Total Parent Net Equity	35.9	20.8	11.2	6.6
Total Liabilities and Shareholders' Equity	37.9	23.8	17.0	16.0
Liquidity				
Current Ratio	18.8x	9.0x	2.9x	1.6x
Quick Ratio	0.0x	0.7x	0.8x	0.8x
Working Capital	35.87	20.45	10.58	5.98

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENT

Incannex Healthcare Inc.

Consolidated Statements of Income (in \$M, except per share amounts)

Fiscal Year End: June

	FY 2021	FY 2022	FY 2023	Q1 Sep-23	Q2 Dec-23	Q3 Mar-24	Q4 Jun-24	FY 2024	Q1 Sep-24	Q2 E Dec-24	Q3 E Mar-25	Q4 E Jun-25	FY 2025E	Q1 E Sep-25	Q2 E Dec-25	Q3 E Mar-26	Q4 E Jun-26	FY 2026E
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ 0.0	\$ 0.1	\$ 0.1	\$ 0.1	\$ 0.1	\$ 0.3	\$ 0.1	\$ 0.1	\$ 0.1	\$ 0.1	\$ 0.5
Other Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Revenues	-	-	-	-	-	-	0.0	0.0	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.5
Research and Development Costs	5.4	9.4	6.3	2.6	2.6	3.3	4.4	12.9	2.9	7.0	7.0	7.0	23.9	7.5	7.5	7.5	7.5	30.0
Acquisition of In-Process R&D	-	-	35.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative	10.3	12.0	8.0	2.3	5.3	4.1	5.4	17.2	3.4	4.0	4.0	4.0	15.4	4.2	4.2	4.2	4.2	16.6
Total Operating Expenses	15.7	21.4	49.7	4.9	8.0	7.4	9.8	30.1	6.3	11.0	11.0	11.0	39.3	11.7	11.7	11.7	11.7	46.6
Operating Income	(15.7)	(21.4)	(49.7)	(4.9)	(8.0)	(7.4)	(9.8)	(30.0)	(6.3)	(10.9)	(10.9)	(10.9)	(39.0)	(11.5)	(11.5)	(11.5)	(11.5)	(46.1)
R&D Tax Incentive	0.8	1.0	0.7	4.1	2.7	1.3	3.3	11.4	0.8	3.0	3.0	3.0	9.9	3.3	3.3	3.3	3.3	13.1
Foreign Exchange Expense	-	-	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Interest Income	0.0	0.4	0.2	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2
Profit Before Taxes	(14.9)	(20.0)	(48.8)	(0.7)	(5.2)	(6.0)	(6.4)	(18.4)	(5.4)	(7.8)	(7.8)	(7.8)	(28.9)	(8.2)	(8.2)	(8.2)	(8.2)	(32.9)
Provision for Income Tax	-	-	-	-	-	-	0.0	0.0	-	-	-	-	-	-	-	-	-	-
Net Income	(14.9)	(20.0)	(48.8)	(0.7)	(5.2)	(6.0)	(6.5)	(18.5)	(5.4)	(7.8)	(7.8)	(7.8)	(28.9)	(8.2)	(8.2)	(8.2)	(8.2)	(32.9)
Basic EPS	\$ (1.25)	\$ (1.30)	\$ (3.32)	\$ (0.05)	\$ (0.33)	\$ (0.38)	\$ (0.39)	\$ (1.15)	\$ (0.29)	\$ (0.44)	\$ (0.44)	\$ (0.44)	\$ (1.61)	\$ (0.46)	\$ (0.46)	\$ (0.46)	\$ (0.46)	\$ (1.83)
Diluted EPS	\$ (1.25)	\$ (1.30)	\$ (3.32)	\$ (0.05)	\$ (0.33)	\$ (0.38)	\$ (0.39)	\$ (1.15)	\$ (0.29)	\$ (0.44)	\$ (0.44)	\$ (0.44)	\$ (1.61)	\$ (0.46)	\$ (0.46)	\$ (0.46)	\$ (0.46)	\$ (1.83)
WTD Shares Out - Basic	11.9	15.4	15.4	15.9	15.9	15.9	16.7	16.2	17.6	17.6	17.6	17.6	18.0	18.0	18.0	18.0	18.0	18.0
WTD Shares Out - Diluted	11.9	15.4	15.4	15.9	15.9	15.9	16.7	16.2	17.6	17.6	17.6	17.6	18.0	18.0	18.0	18.0	18.0	18.0

Growth Rate Y/Y																		
Total cost of revenues		36.1%	132.6%	-87.2%	119.4%	103.1%	133.0%	-39.5%	29.3%	37.8%	48.3%	12.7%	30.9%	84.1%	5.9%	5.9%	5.9%	18.5%
Operating Income		36.1%	132.6%	-87.2%	119.4%	103.1%	132.7%	-39.5%	27.8%	36.8%	47.1%	11.8%	29.8%	84.5%	5.7%	5.7%	5.7%	18.3%
Pre-Tax Income		34.1%	144.3%	-98.1%	79.6%	68.9%	54.0%	-62.2%	645.5%	49.5%	29.8%	21.6%	56.8%	52.0%	5.1%	5.1%	5.2%	13.9%
Net Income		34.1%	144.3%	-98.1%	79.6%	68.9%	54.8%	-62.2%	645.5%	49.5%	29.8%	21.0%	56.5%	52.0%	5.1%	5.1%	5.2%	13.9%

Source: Company Reports, Stonegate Capital Partners estimates

IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate's equity affiliate, Stonegate Capital Partners, "SCP" has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

Ratings - Stonegate does not provide ratings for the covered companies.

Distribution of Ratings - Stonegate does not provide ratings for covered companies.

Price Chart - Stonegate does not have, nor has previously had, a rating for its covered companies.

Price Targets - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

Regulation Analyst Certification:

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

For Additional Information Contact:

Stonegate Capital Partners, Inc.

Dave Storms, CFA

Dave@stonegateinc.com

214-987-4121

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Partners and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Partners is prohibited. Additional information on any securities mentioned is available on request.
